On Monday, Shares Rite Aid Corporation (NYSE:RAD), subtract -0.14% and closed at $7.26 in the last trading session. The last trading range of the stock ranges between $7.23 and $7.40. The company’s Market capitalization is $7.89 Billion with the total Outstanding Shares of 1.05 billion. During the 52-week trading session the minimum price at which share price traded, registered at $ 6.33 and reached to max level of $8.30. The EPS of company is strolling at 0.13. Rite Aid stores nationwide are now able to offer American Express Card Members participating in the Membership Rewards® program the opportunity to use Membership Rewards® points for eligible purchases. Eligible American Express Card Members, who have accumulated enough Membership Rewards® points to pay for their purchase, will be prompted to use points for their purchases after they swipe, tap or insert a Membership Rewards-enrolled American Express Card in-store. Rite Aid is the first pharmacy chain to offer Card Members the opportunity to use Membership Rewards® points for their purchases.
“At Rite Aid, we know how much our customers value choice and convenience, which is why we are excited to be the first pharmacy chain to offer American Express Card Members the opportunity to use Membership Rewards® points for their purchases,” said Ken Martindale, CEO of Rite Aid stores and president of Rite Aid Corporation. “Thanks to our partnership with American Express, in one quick and easy motion, our customers can use the points they’ve accrued through the Membership Rewards® program for their purchases, saving them both money and time.”
Shares of Gilead Sciences, Inc. (NASDAQ:GILD), jumped 0.43% and closed at $76.75 in the last trading session. The last trading range of the stock ranges between $76.07 and $77.12. The company’s Market capitalization is $99.27 Billion with the total Outstanding Shares of 1.32 billion. During the 52-week trading session the minimum price at which share price traded, registered at $71.39 and reached to max level of $108.63. The EPS of company is strolling at10.78. Gilead Sciences (GILD) recently declared detailed results from an open-label Phase 2 trial evaluating the investigational apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib (formerly GS-4997) alone or in combination with the monoclonal antibody simtuzumab (SIM) in patients with nonalcoholic steatohepatitis (NASH) and moderate to severe liver fibrosis (fibrosis stages F2 or F3). The data demonstrate regression in fibrosis that was, in parallel, associated with reductions in other measures of liver injury in patients treated with selonsertib for 24 weeks. These data were presented in a late-breaking abstract session at The Liver Meeting® 2016 in Boston (#LB-3).